Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None

PI Accessory Mutations: None

PR Other Mutations: L10V == . L63T =

Protease Inhibitors

Susceptible atazanavir/r (ATV/r) darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

PR comments

Other

- L10(V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- . K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None NNRTI Mutations: None

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

zidovudine (AZT)

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

tenofovir (TDF)

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

Susceptible

Susceptible

RT comments

Mutation scoring: RT

Other

V179 is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTL

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None INSTI Accessory Mutations: None

Integrase Strand Transfer Inhibitors

bictegravir (BIC) Susceptible
cabotegravir (CAB) Susceptible
dolutegravir (DTG) Susceptible
elvitegravir (EVG) Susceptible
raltegravir (RAL) Susceptible

Mutation scoring: IN
HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.